Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Expert Rev Neurother. 2011 Jul;11(7):1057–1075. doi: 10.1586/ern.11.69

Figure 5. Mean fall frequency was almost 50% lower during the 6-week period when subjects with Parkinson’s disease were taking donepezil, compared with the 6-week period when they were taking placebo.

Figure 5

Note that those subjects who had relatively high fall frequencies on placebo seemed to be most responsive to donepezil.

Data from [123].